The potential impact of new effervescent alendronate formulation on compliance and persistence in osteoporosis treatment.

Details

Ressource 1Request a copy Sous embargo indéterminé.
State: Public
Version: Final published version
License: Not specified
Serval ID
serval:BIB_21A4633BADBE
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
The potential impact of new effervescent alendronate formulation on compliance and persistence in osteoporosis treatment.
Journal
Aging Clinical and Experimental Research
Author(s)
Invernizzi M., Cisari C., Carda S.
ISSN
1720-8319 (Electronic)
ISSN-L
1594-0667
Publication state
Published
Issued date
2015
Peer-reviewed
Oui
Volume
27
Number
2
Pages
107-113
Language
english
Notes
Publication types: Journal Article Publication Status: ppublish
Abstract
Osteoporotic fractures are a public health problem and their incidence and subsequent economic and social costs are expected to rise in the next future. Different drugs have been developed to reduce osteoporosis and the risk of osteoporotic fractures, and among them, antiresorptive agents, and in particular oral alendronate, are the most widely utilized. However, one of the most common problems with antiresorptive drugs is poor adherence to treatment, which is associated with a high fracture incidence and with an increase in hospitalization costs. One of the main reasons of poor adherence to these treatments is the occurrence of adverse events, mainly at gastrointestinal (GI) level, including dyspepsia, dysphagia, and esophageal ulcers. In light of these considerations the aim of this paper is to perform a literature review to show the pathophysiologic bases of GI alendronate-induced adverse events and how new bisphosphonate formulations like effervescent alendronate can improve compliance and persistence to treatment and decrease the fracture rate incidence in osteoporotic patients.
Keywords
Osteoporosis, Bone loss, Bisphosphonates, Alendronate, Adverse effects
Pubmed
Web of science
Create date
18/04/2015 13:21
Last modification date
29/08/2020 7:08
Usage data